We are live on
!
Find out more
PCH
Polar Capital Holdings Portfolio holdings
AUM
$42.4B
1-Year Est. Return
181.11%
This Fund
S&P 500
This Quarter
Est. Return
+14.73%
1 Year Est. Return
+181.11%
3 Year Est. Return
+584.8%
5 Year Est. Return
+777.19%
10 Year Est. Return
–
AUM
$19.8B
AUM Growth
+$4.43B
(+29%)
Cap. Flow
-$459M
Cap. Flow
% of AUM
-2.31%
Top 10 Holdings %
Top 10 Hldgs %
44.52%
Holding
334
New
39
Increased
100
Reduced
95
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Synopsys
SNPS
|
+$124M |
| 2 |
McKesson
MCK
|
+$123M |
| 3 |
Amazon
AMZN
|
+$72.5M |
| 4 |
Rambus
RMBS
|
+$72.1M |
| 5 |
Indivior Pharmaceuticals
INDV
|
+$69.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$102M |
| 2 |
Teradyne
TER
|
+$90.7M |
| 3 |
Apple
AAPL
|
+$80M |
| 4 |
United Therapeutics
UTHR
|
+$72.6M |
| 5 |
Visa
V
|
+$71.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.14% |
| 2 | Miscellaneous | 28.15% |
| 3 | Healthcare | 17.87% |
| 4 | Financials | 12.12% |
| 5 | Communication Services | 6.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Viridian Therapeutics
VRDN
$2.52B
| $38.1M | 0.19% |
1,600,000
+1,050,000
| +191% | +$26.9M |
|
102
Trip.com Group
TCOM
$24.6B
| $37.9M | 0.19% |
1,083,084
-1,265,806
| -54% | -$44M |
|
103
Rhythm Pharmaceuticals
RYTM
$7.05B
| $37.1M | 0.19% |
2,250,000
+500,000
| +29% | +$9.03M |
|
104
BioMarin Pharmaceuticals
BMRN
$12.9B
| $36.8M | 0.19% |
425,000
| – | – |
|
105
Aflac
AFL
$58.7B
| $36.3M | 0.18% |
520,000
| – | – |
|
106
Enphase Energy
ENPH
$4.84B
| $36.1M | 0.18% |
215,656
+19,472
| +10% | +$3.48M |
|
107
LivaNova
LIVN
$4.44B
| $35.8M | 0.18% |
696,726
+40,310
| +6% | +$1.89M |
|
108
Insmed
INSM
$27.4B
| $35.7M | 0.18% |
1,691,349
| – | – |
|
109
Becton Dickinson
BDX
$48.4B
| $35.6M | 0.18% |
+134,996
| New | +$34.3M |
|
110
RLI Corp
RLI
$5.63B
| $35.5M | 0.18% |
520,000
| – | – |
|
111
Neurocrine Biosciences
NBIX
$16B
| $35.4M | 0.18% |
+375,000
| New | +$36.6M |
|
112
Addus HomeCare
ADUS
$2.19B
| $35.2M | 0.18% |
379,913
| – | – |
|
|
KRTX
113
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $32.8M | 0.17% |
+151,450
| New | +$32.4M |
|
|
PRA
114
DELISTED
ProAssurance
PRA
| $32.6M | 0.16% |
2,162,500
| – | – |
|
|
BPMC
115
DELISTED
Blueprint Medicines
BPMC
| $31.6M | 0.16% |
+500,000
| New | +$27.2M |
|
116
US Foods
USFD
$20.5B
| $31.5M | 0.16% |
716,350
-67,211
| -9% | -$2.67M |
|
117
Dynatrace
DT
$15.4B
| $31.2M | 0.16% |
605,555
-69,848
| -10% | -$3.27M |
|
118
Arcutis Biotherapeutics
ARQT
$3.05B
| $29.8M | 0.15% |
3,127,777
-7,736
| -0.2% | -$85.9K |
|
119
Denali Therapeutics
DNLI
$3.39B
| $29.7M | 0.15% |
1,007,086
+502,086
| +99% | +$14.1M |
|
120
Pliant Therapeutics
PLRX
$72.4M
| $29.7M | 0.15% |
1,640,000
-143,164
| -8% | -$3.39M |
|
|
CERE
121
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $29M | 0.15% |
910,762
+142,486
| +19% | +$4.37M |
|
122
Amdocs
DOX
$6.41B
| $26.9M | 0.14% |
272,271
-1,539
| -0.6% | -$145K |
|
123
Veeva Systems
VEEV
$43B
| $25.5M | 0.13% |
128,876
+46,957
| +57% | +$8.56M |
|
124
Alcon
ALC
$32.7B
| $25.5M | 0.13% |
310,082
-24,505
| -7% | -$1.87M |
|
125
Qiagen
QGEN
$8.65B
| $25.4M | 0.13% |
531,202
+116,052
| +28% | +$5.59M |
|
Similar funds
GAM
SAM
Polar Capital Holdings's Q2 2023 Portfolio in Review
As of Q2 2023, Polar Capital Holdings held 334 positions worth $19.8B, up 29% from $15.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Polar Capital Holdings's Q2 2023 filing shows 39 new, 100 increased, 95 reduced and 48 closed positions. Its largest new stake was Synopsys: 308,727 shares worth $134M. The largest sale was Microsoft, an estimated $102M.
By sector, the portfolio is most concentrated in Technology at 30% of assets, down from 36% a quarter earlier, followed by Miscellaneous and Healthcare.
- Polar Capital Holdings's largest Q2 2023 buy was Synopsys: 308,727 shares worth $134M.
- Polar Capital Holdings added most to Amazon in Q2 2023, an estimated $72.5M increase.
- Polar Capital Holdings's biggest Q2 2023 reduction was Microsoft, cutting an estimated $102M.
- Polar Capital Holdings fully exited Teradyne in Q2 2023, selling an estimated $90.7M.
- Polar Capital Holdings's ten largest holdings make up 45% of its $19.8B portfolio in Q2 2023.
- Polar Capital Holdings opened 39 new positions and closed 48 in Q2 2023.
- Polar Capital Holdings's portfolio value rose 29% quarter-over-quarter to $19.8B.
Based on Polar Capital Holdings's 13F filing for Q2 2023, filed 14 Aug 2023.